ABP-ADP-1 is a preparation of adenosine -5’-disphophate (ADP) that mimics the physiologic release of ADP following blood vessel injury. It is used in routine platelet aggregation studies for the evaluation of inherited or acquired platelet dysfunctions, platelet activation, and the effects of anti-platelet therapy. It is sensitive to the effects of P2Y12 inhibitors and to the action of glycoprotein (Gp) IIb/IIIa receptor antagonists and/or a deficiency of GpIIb/IIIa receptors. It is insensitive to the effects of aspirin and aspirin-like drugs.
ABP-ADP-1 is supplied as three separate vials, each containing 100 nmol of lyophilized ADP. When reconstituted in 500 µL of purified water, the stock solution is 0.2 mM. Once reconstituted, the reagent is stable for 30 days when stored at 4oC to 8oC. Prior to use, reagent should be brought to room temperature.
Upon addition of ADP, platelets activate, change shape, and aggregate. This primary aggregation is reversible (disaggregation). Normal platelets will further respond by releasing endogenously stored ADP from dense (delta) granules leading to a second, irreversible wave of aggregation. Clopidegrel, and related drugs, block the P2Y12 receptor, believed to be the most important receptor for ADP on the platelet surface.